Deepull debuts point of care sepsis detection UllCORE system

Phalguni Deswal
2 min read
0
In this article:

Spanish medical diagnostics company Deepull to debut its point of care diagnostic UIICORE diagnostics system for detection of sepsis.

Sepsis is the third leading cause of death in US hospitals. The Centers for Disease Control and Prevention (CDC) estimates that 1.7 million adults in the US develop sepsis each year, with 350,000 dying as a result. There is no single diagnostic test for sepsis, a combination of blood tests usually diagnoses it.

UIICORE system uses polymerase chain reaction (PCR) to extract microbial DNA from the human blood sample. The test covers 95% of sepsis-causing pathogens, including bacteria and fungi, and antibiotic resistance genes and provides results in one hour. The normal culture test can take over three days to give results.

Deepull plans to unveil the UIICORE system at the ESCMID Global 2024 conference, taking place in Barcelona from 27-30 April. The company also plans to seek partnerships with hospitals and laboratories.

“We are encouraged by early results based on prospectively obtained specimens from septic patients and look forward to initiating clinical trials next year, as well as refining the platform ahead of commercial launch,” said Deepull CEO Jordi Carrera.

The use point-of-care diagnostics has increased following the Covid-19 pandemic. The in vitro diagnostics market is expected to grow to be worth $38.5bn in 2030, as per a GlobalData market model.

Other companies developing sepsis detection technologies include Asep Medical. In June 2023, the company unveiled an artificial intelligence (AI) technology for the rapid detection of infections associated with severe sepsis. Mednition also received breakthrough device designation from the US Food and Drug Administration (FDA) for its AI-powered sepsis solution, KATE Sepsis.

In November 2023, Cytovale raised $84m in a Series C funding round to continue the rollout of its sepsis diagnosis test, IntelliSep rapid sepsis diagnosis test. The test allocates patients into three bands based on their sepsis probability using a standard blood sample. It assesses the body’s immune response to an infection and delivers results within ten minutes.

"Deepull debuts point of care sepsis detection UllCORE system" was originally created and published by Medical Device Network, a GlobalData owned brand.


 


The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Advertisement

Recommended Stories

  • Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial

    A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters

  • 5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge

    Investors look to profit from surging demand for new weight-loss drugs.

  • Regeneron gene therapy improves hearing in two children

    The results add to an early but growing body of evidence suggesting gene therapy may improve outcomes in young kids with a genetic form of deafness.

  • 5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip

    New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy now and hold over the long run.

  • Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

    Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?

  • Vertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks Shares

    Vertex stock advanced Tuesday as analysts debated the company's pain drug with one saying it could eventually generate $11.4 billion in sales.

  • Pfizer reports fatality in Phase II DMD gene therapy study

    The company paused participant dosing associated with the crossover portion of its Phase III CIFFREO trial.

  • Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates

    Teva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. In the wake of February's U.S. Food and Drug Administration approval of Humira biosimilar Simlandi, Teva chief executive Richard Francis said the launch will be during the second quarter. "I don't have exact timetables but it's imminent," he told Reuters, adding Teva has been in "lots and lots of discussions" with pharmacy benefit managers (PBMs) and payers.

  • Just One Human Is Infected by Bird Flu in the US. More Cases Are Likely

    (Bloomberg) -- It’s spreading rapidly among cows. It’s also infecting skunks, mountain lions and red foxes.Most Read from BloombergAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsStormy Daniels Will Return to Court in Test of Trump’s DemeanorTrump Judge Indefinitely Postpones Documents Case TrialYet as the highly contagious avian flu affects mammals across the US, just one human case has been reported so far.But that

  • What About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month

    Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa